Mostrar registro simples

dc.contributor.authorWilke, Matheus Vernet Machado Bressanpt_BR
dc.contributor.authorOliveira, Bibiana Mello dept_BR
dc.contributor.authorStarosta, Rodrigo Tzovenospt_BR
dc.contributor.authorShinawi, Marwanpt_BR
dc.contributor.authorLu, Liangpt_BR
dc.contributor.authorHe, Maipt_BR
dc.contributor.authorMa, Yaminpt_BR
dc.contributor.authorStoll, Janispt_BR
dc.contributor.authorSouza, Carolina Fischinger Moura dept_BR
dc.contributor.authorSiqueira, Ana Cecilia Menezes dept_BR
dc.contributor.authorVieira, Sandra Maria Gonçalvespt_BR
dc.contributor.authorCerski, Carlos Thadeu Schmidtpt_BR
dc.contributor.authorRefosco, Lilia Farretpt_BR
dc.contributor.authorSchwartz, Ida Vanessa Doederleinpt_BR
dc.date.accessioned2023-11-18T03:26:58Zpt_BR
dc.date.issued2023pt_BR
dc.identifier.issn2227-9059pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/267289pt_BR
dc.description.abstractGlycogen storage disease type IV (GSD IV) is an ultra-rare autosomal recessive disease caused by variants in the GBE1 gene, which encodes the glycogen branching enzyme (GBE). GSD IV accounts for approximately 3% of all GSD. The phenotype of GSD IV ranges from neonatal death to mild adult-onset disease with variable hepatic, muscular, neurologic, dermatologic, and cardiac involvement. There is a paucity of literature and clinical and dietary management in GSD IV, and liver transplantation (LT) is described to correct the primary hepatic enzyme defect. Objectives: We herein describe five cases of patients with GSD IV with different ages of onset and outcomes as well as a novel GBE1 variant. Methods: This is a descriptive case series of patients receiving care for GSD IV at Reference Centers for Rare Diseases in Brazil and in the United States of America. Patients were selected based on confirmatory GBE1 genotypes performed after strong clinical suspicion. Results: Pt #1 is a Latin male with the chief complaints of hepatosplenomegaly, failure to thrive, and elevated liver enzymes starting at the age of 5 months. Before LT at the age of two, empirical treatment with corn starch (CS) and high protein therapy was performed with subjective improvement in his overall disposition and liver size. Pt #2 is a 30-month-old Afro-American descent patient with the chief complaints of failure to gain adequate weight, hypotonia, and hepatosplenomegaly at the age of 15 months. Treatment with CS was initiated without overall improvement of the symptoms. Pt #3.1 is a female Latin patient, sister to pt #3.2, with onset of symptoms at the age of 3 months with bloody diarrhea, abdominal distention, and splenomegaly. There was no attempt of treatment with CS. Pt #4 is an 8-year-old male patient of European descent who had his initial evaluation at 12 months, which was remarkable for hepatosplenomegaly, elevated ALT and AST levels, and a moderate dilatation of the left ventricle with normal systolic function that improved after LT. Pt #1, #3.2 and #4 presented with high levels of chitotriosidase. Pt #2 was found to have the novel variant c.826G > C p.(Ala276Pro). Conclusions: GSD IV is a rare disease with different ages of presentation and different cardiac phenotypes, which is associated with high levels of chitotriosidase. Attempts of dietary intervention with CS did not show a clear improvement in our case series.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofBiomedicines. Basel. Vol. 11, no. 2 (Jan. 2023), article 363, 10 p.pt_BR
dc.rightsOpen Accessen
dc.subjectGlycogen storage disease IVen
dc.subjectDoença de depósito de glicogênio tipo IVpt_BR
dc.subjectTransplante de fígadopt_BR
dc.subjectLiver transplantationen
dc.subjectDietoterapiapt_BR
dc.subjectDietary treatmenten
dc.titleA broad characterization of glycogen storage disease iv patients : a clinical, genetic, and histopathological studypt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001186998pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples